Lilly’s Protomer deal shows innovation in diabetes is not dead
Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.
Combining forces in metabolic disorders
Altimmune’s early-stage obesity hit is impressive, but big pharma has more advanced rivals.
Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Lilly leads the big pharma pack on pipeline value
Huge hopes for diabetes and Alzheimer’s projects swell Lilly’s pipeline valuation, with Glaxosmithkline and Abbvie looking bare in comparison.
